Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in daily clinical practice.
R
etinal vein occlusion (RVO) is a vascular disease that is caused by an obstruction in either a branch retinal vein (BRVO) or in the central retinal vein (CRVO). This leads to a retinal edema that can seriously reduce visual acuity when the fovea is involved. Branch retinal vein occlusion can improve spontaneously but can also deteriorate further whereas CRVO rarely improves spontaneously and often deteriorates without treatment.
1,2 Treatment of macular edema in RVO has long posed a challenge to clinicians. Until recently, the guiding principle for the management of unresolving BRVO was central grid laser, whereas no treatment was available for CRVO. 3 Intraocular vascular endothelial growth factor (VEGF) is highly elevated in RVO, 4, 5 and novel therapeutic approaches have emerged for the management of macular edema in RVO such as intravitreal corticosteroid injections and intravitreal anti-VEGF injections. BRAVO 6 and CRUISE
7
-two large randomized multicenter studiesrecently found ranibizumab (Lucentis; Novartis, Basel, Switzerland) beneficial for BRVO and CRVO, and the Danish Health and Medicines Authority approved intravitreal injections with ranibizumab for RVO in January 2011. Daily clinical practice is often different from the setting of randomized clinical trials. We, therefore, prospectively collected treatment data of all patients receiving intravitreal ranibizumab for CRVO and BRVO at our department to evaluate and compare the efficacy and safety with the randomized controlled trials that led to the introduction of the therapy.
Material and Methods

Patients
We consecutively included all patients with RVO who received intravitreal ranibizumab from January 2011 to April 2013. Patient data were continuously updated in a database. We excluded patients with diabetic macular edema, severe macular traction, previous injection with dexamethasone implant, or cataract surgery during the treatment period. The first visit after the initiation of ranibizumab therapy was defined as the 5-month follow-up. The visit in the range 9 to 15 months closest to 12 months was defined as the 12-month follow-up. If a patient was discontinued from further treatment before 9 months, the last observation was carried forward for the 12-month analysis. Patients diagnosed with hemicentral vein occlusion were considered as BRVO in line with the criteria for the BRAVO study. 7 All patients who had received a minimum of one intravitreal injection with ranibizumab for RVO were included in the safety analysis.
Clinical Examination and Outcome Measures
At the first visit, a full medical history was taken. Slit-lamp and fundus biomicroscopic examinations were performed in all patients. Best-corrected visual acuity (BCVA) testing was performed using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual chart (CC-100, Topcon Corporation, Tokyo, Japan), and the intraocular pressure was determined using rebound tonometry (Icare; Icare Finland Oy, Helsinki, Finland) followed by Goldmann applanation tonometry if ocular hypertension or glaucoma was suspected. Spectral domain optical coherence tomography (Spectralis HRA-OCT; Heidelberg Engineering, Heidelberg, Germany) scanning was performed in all eyes using eye-tracking for follow-up measurements to maximize intersession repeatability. 8 Foveal center point thickness (CPT) was assessed using the manufacturer's proprietary software (Heidelberg Eye Explorer 1.7.1.0). Fluorescein angiography was not routinely performed and neither was the assessment of the presence of an afferent papillary defect. The duration of symptoms was defined as the patients' subjective assessment of symptom duration by the initiation of anti-VEGF therapy. Serous macular detachment was defined as the presence of fluid under the neuroretina but above the retinal pigment epithelium layer determined by spectral domain optical coherence tomography. We considered a gain of 15 ETDRS letters or more as functional success, 9 and reaching a CPT below 275 mm-with Heidelberg equipment-as anatomical success. 10 
Patient Management
Treatment, monitoring, and decision regarding retreatment or discontinuation of treatment followed the Danish National guidelines set forward by the Danish Ophthalmological Society. Intravitreal anti-VEGF was initiated in all patients with visual impairment deemed to result from subfoveal edema secondary to RVO. All patients were treated promptly after diagnosis. An exception was BRVO patients with initial BCVA of more than 70 ETDRS letters who were observed for 3 months for spontaneous resolution. Anti-VEGF treatment was usually initiated as a series of 3 intravitreal injections of 0.5 mg ranibizumab each month for 3 months followed by a follow-up examination 1 to 2 months after the third injection. We continued with 1 to 3 monthly injections if there was an improvement in the BCVA or on spectral domain optical coherence tomography, unless the macula was devoid of edema. Causes of discontinuation were unchanged/decreased BCVA and/or lack of improvement on spectral domain optical coherence tomography. In BRVO, adjuvant central photocoagulation was applied in the case of unsatisfactory response to intravitreal therapy at the investigators discretion. Panretinal laser photocoagulation was applied if retinal neovascularizations developed.
Data Analysis
The changes in both BCVA and CPT followed a normal distribution, and a paired student's t-test was performed comparing baseline BCVA and CPT to 5 months and baseline to 12 months for both BRVO and CRVO. Multiple linear regression analysis with backward elimination was performed pooled for all patients with change in BCVA or CPT as dependent variables. The data were analyzed using SAS 9.3 (SAS Institute Inc, Cary, NC). A P value less than 0.05 was considered significant.
Results
Patients
One hundred and twenty patients had attended the first follow-up visit. Fourteen patients were excluded (2 had diabetic macular edema, 1 had severe vitreomacular traction, 10 had received an intravitreal sustained release implant before ranibizumab treatment, and 1 underwent cataract surgery during the treatment period). Seventy-four of the remaining 106 patients had follow-up through at least 9 months and were included for the 12-month analysis. The baseline data are shown in Table 1 . Patients with BRVO had received a median of 5 (interquartile range, 3-5.5) injections whereas patients with CRVO had received a median of 6 (interquartile range, 3-6) injections. Four patients received bilateral treatment. Six patients were discontinued before 9 months of follow-up because of: nonresponse and change to dexamethasone implant therapy (n = 2), nonresponse in patients with very poor baseline visual acuity (n = 2), or development of neovascular glaucoma (n = 2). Five patients had received macular laser before initiating intravitreal ranibizmab, and one patient had central grid laser performed after ranibizumab treatment was initiated. Median follow-up was 9.7 months (interquartile range, 5.1-12.8) for BRVO patients and 11.2 months (interquartile range, 6.5-13.0) for CRVO patients.
Functional Outcome
Patients with BRVO improved a mean of 9.4 (P , 0.0001) ETDRS letters at Month 5 and 11.6 letters at Month 12 (P , 0.0001). Patients with CRVO improved a mean of 5.7 letters (P , 0.0001) at Month 5 and 1.8 letters at Month 12 (P = 0.50) ( Table 2) .
In BRVO, 31.6% gained 15 ETDRS letters or more at 5 months and 26.3% at 12 months. An additional 28.9% gained 10 to 14 letters at 12 months. Only 1.8% and 0% lost 15 letters or more at 5 months and 12 months, respectively (Figure 1 ). In CRVO, 24.5% gained 15 letters or more at 5 months, but only 16.7% by 12 months, and just 11.1% gained 10 to 14 letters. A total of 6.1% and 8.3% lost 15 ETDRS letters or more by 5 months and 12 months, respectively (Figure 2 ).
We performed a multiple linear regression analysis for all patients combined, adjusting for age, gender, type of retinal occlusion, ocular tension, presence of serous macular detachment, subjective duration of ocular symptoms, BCVA, and CPT. Younger patients gained 0.45 ETDRS letter (95% confidence interval [CI], 0.13-0.71, P , 0.0001) per year of age. Patients with lower baseline BCVA gained 0.21 ETDRS letters (95% CI, 0.05-0.37, P = 0.01) per affected letter at baseline. At 5 months, there was no significant difference between patients with CRVO and BRVO (P = 0.1). By 12 months, BRVO patients had an adjusted 8.8 ETDRS letters (95% CI, 3.4-14.3, P = 0.002) improvement over CRVO patients. Patients with serous macular detachment improved 7.3 ETDRS letters at 5 months (95% CI, 2.2-12.6, P = 0.006), but the difference was −2.0 letters at 12 months (95% CI, −7.6 to 3.6, P = 0.49). SEM, standard error of the mean.
Anatomical Outcome
In BRVO, there was a reduction in CPT of 217 mm at 5 months (P , 0.0001) and of 248 mm at 12 months (P , 0.0001). In CRVO, the reduction in CPT was 192 mm (P , 0.0001) and 222 mm (P , 0.0001), respectively ( Table 2) .
We performed a multiple linear regression analysis for CPT adjusting for the same factors as in the functional outcome. Younger patients improved 5 mm (95% CI, 1.1-9.2, P = 0.01) more in CPT per year of age at 12 months, and patients with thicker retina improved 0.5 mm (95% CI, 0.26-0.74, P = 0.0001) per micrometer of CPT at baseline. There was no difference between BRVO versus CRVO at 5 (P = 0.77) or 12 months (P = 0.85). Serous macular detachment at baseline led to an adjusted improved reduction in CPT of 99.4 mm (95% CI, 5-194, P = 0.04) at 12 months.
Functional and Anatomical Outcome Combined
We compared the functional and anatomical success criteria in Table 3 . In total, 22% to 31% reached the anatomical success without accompanying functional success. There was no clear pattern between achieving functional success and the corresponding anatomical status. The proportion of patients who achieved neither success criteria was 45% to 53%.
Safety
A total of 617 injections have been given for RVO at our department including patients treated beyond 12 months and patients excluded for the efficacy analysis. No sight-threatening ocular adverse events were recorded. One patient experienced a nonfatal ischemic stroke 3 days after his third ranibizumab injection. A computer tomography of the cerebrum however only revealed signs of older minor infarctions.
Discussion
We found our BCVA results for BRVO to be within our expectations, but for CRVO, the mean improvement of 1.8 letters at 12 months was below our expectations. The reduction in CPT was satisfactory for both groups, but the visual gain did not appear to mirror the decreased macular edema as 22% to 31% reached the anatomical success criteria without an accompanying significant improvement in BCVA.
Daily clinical practice is different from the setting of randomized controlled clinical trials. First, the inclusion criteria of BRAVO and CRUISE differed from our study. The randomized trials did not include patients with BCVA above 70 ETDRS letters (0.5 Snellen equivalents), a group of patients with less potential to improve vision by 15 ETDRS letters or more because of ceiling effect. Patients with baseline visual acuity below 20/400 (approximately 20 ETDRS letters) were not included in BRAVO and CRUISE, a group of patients so severely affected that improvement is less likely. In Table 4 , we have compared our patients with baseline BCVA between 20 and 70 letters with the randomized trials. This subgroup has slightly better results, but both in BRVO and CRVO, our results were superior to the sham arms and inferior to the 2 treatment arms of the randomized trials. BRAVO and CRUISE did not have a sham or 0.3 ranibizumab arm at 12 months because those patients were converted to a 0.5-mg ranibizumab dosing regimen. Second, BRAVO and CRUISE had several exclusion criteria that we did not. For instance, patients with brisk afferent pupillary defect or previous RVO were excluded in those studies. Pupillary defect is often caused by extensive capillary nonperfusion, and such patients would be expected to improve less. We have no reliable estimation of the number of patients with afferent pupillary defect in our cohort, and we did not perform fluorescein angiography routinely. A high degree of retinal ischemia in our CRVO patients could have negatively affected our results. Third, our patients were solely white and older than the ethnically mixed participants of BRAVO and CRUISE. Older age has been found to be a risk factor for poorer visual prognosis in untreated CRVO, 11 and we also found this association in our regression analysis. Fourth, the treatment regimen differed. The therapy in BRAVO and CRUISE was initiated with an injection each month for 6 consecutive months followed by injections as needed, whereas we usually initiated therapy with 3 injections 1 month apart followed by usually 8 weeks of observation before further observation and retreatment. Eight weeks of follow-up compares with 4 weeks in the randomized controlled trials, and the edema may have returned in the interim period. Although we endeavor a 4-week to 6-week interval for follow-up, our department is time constrained because of a constant rise in the number of patients undergoing anti-VEGF treatment. Because of all these differences between randomized controlled clinical trials and our daily clinical practice, it is to be expected that our results are less impressive. However, the level of [12] [13] [14] and only few of our patients had a decrease in BCVA.
The results of the present study have prompted us to change our local treatment guidelines to address concerns of undertreatment and undermonitoring and more closely follow the BRAVO and CRUISE regimen. Our study does not address the role of dexamethasone implants in RVO. Six (46%) of the 13 patients with hemicentral retinal vein occlusion gained at least 15 ETDRS letters. As in BRAVO, these patients were included in the BRVO group, but hemicentral vein occlusion should ideally be considered a separate disease entity. 15 Our results for this subgroup of patients are encouraging.
Changes in BCVA were only little to moderately related to quality of life changes in BRAVO and CRUISE. 16 This is also our clinical experience, although we have not systematically assessed quality of life changes.
Our CPT measurements were performed with Heidelberg equipment, and the absolute thickness cannot be directly compared with other manufacturer's equipment 8 such as the Stratus (Zeiss) equipment used in the BRAVO and CRUISE studies. The change in CPT should however be similar, and our reduction of 217 mm for BRVO at 5 months compares with 339 mm and 345 mm for the 0.3-mg and 0.5-mg arm versus 158 mm for the sham arm in BRAVO. 6 Similarly, the mean reduction of 192 mm for our CRVO patients at 5 months compares with 435 mm and 453 mm for the 0.3 mg and 0.5 mg ranibizumab versus 168 mm for the sham arm in CRUISE. 7 Similar to the BCVA results, our results are superior to the sham arm and inferior to the treatment arm of BRAVO and CRUISE.
The improved response in younger patients for both CPT and BCVA and with worse baseline BCVA or CPT is consistent with the findings of other studies of ranibizumab for diabetic macular edema 17 and agerelated macular degeneration. 18, 19 To the best of our knowledge, subgroup analysis for this parameter has not yet been published for the BRAVO and CRUISE trials.
Other studies on the role of serous macular detachment have been contradicting: One study found an improved treatment effect in patients with serous macular detachment, 20 whereas subgroup analysis of the BRAVO and CRUISE data did not find the presence of submacular fluid to influence visual outcome. 21 We found that serous macular detachment was related to a slower improvement in visual function, but at 12 months, the visual outcome was similar to patients without serous macular detachment.
Strengths of this study are that almost every patient treated in our daily clinical setting through more than 2 years has been included for analysis. A limitation of this study is the nonrandomized design, and we were unable to control for the natural course of BRVO and CRVO. Though we have made attempts to compare our results with the sham and laser arms of clinical trials, we acknowledge that such comparisons have numerous caveats.
In conclusion, in our daily clinical practice, intravitreal ranibizumab for BRVO led to 12-month visual improvements that were comparable with those of the BRAVO trial that led to the approval of the therapy for BRVO. However, our visual results for CRVO at 12 months failed to reproduce the results of the CRUISE trial that led to the approval of the therapy for CRVO. In both BRVO and CRVO, we found a significant reduction of foveal CPT, but the anatomical outcome did not mirror the functional outcome. Younger and more severely affected patients responded more favourably to the treatment. No safety issues were identified. These results have prompted us to a closer adherence to the treatment protocol of the CRUISE trial for CRVO patients.
